Short answer
Sabra Health Care REIT, Inc. (SBRA) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.4 (Exhibit EX-99.4). Third-quarter 2026 operating results released for the period ended September 30, 2026.
Sabra Health Care REIT, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter 2026 operating results released for the period ended September 30, 2026
- Press release and non-GAAP reconciliations available in Exhibits 99.1 and 99.3
- Investors should review adjusted funds from operations and other REIT metrics in the exhibits for valuation implications
Item 7.01 · Regulation FD Disclosure
- Supplemental information package available in Exhibit 99.2 and on Sabra’s investor website
- Exhibit 99.1 press release and Exhibit 99.4 presentation materials provide the substantive investor information
- Investor materials support review of Sabra’s fiscal-year 2026 results and operating outlook
Item EX-99.1 · Exhibit EX-99.1
- Q3 Normalized FFO $0.39 and Normalized AFFO $0.41 per share, supporting the $0.30 quarterly dividend
- Same-property SHOP Cash NOI increased 14.6% year over year, reinforcing Sabra’s shift toward higher-growth operating assets
- Q3 acquisitions totaled $222.8 million at a 7.7% estimated yield, with $747.2 million invested year to date at 8.0%
- Awarded investments total $425 million, including approximately $385 million of SHOP, creating further funding and execution requirements
- 2026 guidance raised at the midpoint: Normalized FFO $1.545 and Normalized AFFO $1.605 per share; leverage remained moderate at 4.54x
Item EX-99.2 · Exhibit EX-99.2
- Q3 2026 revenues $249.6M, up from $190.0M, driven by resident fees and services of $143.2M
- Normalized AFFO $0.41 per diluted share versus $0.30 dividend, implying quarterly payout coverage of approximately 1.4x
- SHOP expanded to 101 properties and 10,540 units, with occupancy reaching 86.5% and same-store occupancy 89.2%
- Nine-month acquisitions and investments totaled $534.9M at an estimated 8.2% yield, accelerating portfolio growth
- Leverage remained moderate at 4.54x net debt to adjusted EBITDA, with $873.5M revolver availability and 2026 normalized AFFO guidance of $1.600 to $1.610 per share
Item EX-99.3 · Exhibit EX-99.3
- 2026 guidance: Normalized FFO $1.540-$1.550 per share and Normalized AFFO $1.600-$1.610
- Guidance assumes low-single-digit triple-net Cash NOI growth and mid-teens same-store SHOP Cash NOI growth
- Q3 Normalized FFO $0.39 per share, up from $0.36; Normalized AFFO $0.41, up from $0.38
- Nine-month Normalized FFO $1.15 per share and Normalized AFFO $1.20, improving from $1.09 and $1.12
- Net debt $2.418 billion and leverage 4.54x annualized Adjusted EBITDA, a key balance-sheet constraint for capital allocation
Item EX-99.4 · Exhibit EX-99.4
- 2026 guidance midpoint implies Normalized FFO $1.545 per share, approximately 7% year-over-year growth
- Year-to-date investments nearly $750M, approximately 80% SHOP, at estimated 8.0% yield
- Awarded investment pipeline approximately $425M, mostly SHOP, at estimated 7.0% yield
- Same-store SHOP NOI growth guidance in the mid-teens, supporting SHOP’s path toward 40% of NOI
- Balance sheet supports growth: $1.2B liquidity, 4.54x net debt to adjusted EBITDA, BBB- S&P rating with positive outlook
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sabra Health Care REIT, Inc. 8-K filings
Get the next SBRA 8-K as it lands
Follow SBRA for push alerts, or ask the research agent what this filing means.